Japan

The trial will enroll up to 105 Japanese men across 11 sites throughout the country, with the collected data intended to support a future marketing authorization submission for TLX591-Px in Japan.

These investments will focus primarily on companies developing breakthrough technologies in gastrointestinal (GI), urology, and respiratory care.

The two pharmaceutical giants originally signed the agreement in October 2025, establishing a framework centered on bispecific antibodies and ADCs.